N-((9H-fluoren-9-ylmethoxy)carbonyl)-N,O-dimethyl-L-Serine

We have devised a new saccharide derivatization scheme to provide not only the temporary attachment of a chromophore for detecting and facilitating the chromatographic separation of carbohydrates, but also the intermediates for further derivatization to produce neoglycoconjugates. Several neutral unprotected saccharide beta-glycosylamines were formed by the direct condensation of the reducing saccharides with aqueous ammonium bicarbonate. The beta-glycosylamine derivatives of N-acetylglucosamine, di-N-acetylchitobiose, and asialo-, digalactosylated biantennary complex oligosaccharide were N-acylated separately with excess 9-fluorenylmethoxycarbonyl (Fmoc)-glycine. The Fmoc-glycinamido beta-derivatives of these unprotected saccharides were well separated by normal-phase high-performance liquid chromatography and detected by ultraviolet absorption. Similar derivatization and fractionation of a partial acid hydrolyzate of chitin were equally successful resulting in the separation of Fmoc-glycinamido derivatives of di-N-acetylchitobiose to hepta-N-acetylchitoheptaose in the hydrolyzate. The reversibility of the Fmoc derivatization was demonstrated by treating the Fmoc-glycinamido derivative of N-acetylglucosamine with piperidine to generate its 1-N-glycyl-beta-saccharide derivative. The structure and stereochemistry of this product was confirmed by proton nuclear magnetic resonance spectroscopy. The 1-N-glycyl-beta-saccharide derivatives are stable intermediates for the formation of asparagine-linked neoglycoconjugates.

Background: The efficacy of the leukocyte recruitment inhibitor, N-[9H-2,7-dimethylfluoren-9-ylmethoxy)carbonyl]-L-leucine (NPC 15669) was compared with drugs used to treat inflammatory bowel diseases in a rat model, acetic acid-induced colitis. Methods: Colonic damage assessed by visual inspection, histological quantitation of tissue injury, vascular permeability, myeloperoxidase (MPO) accumulation, and synthesis of inflammatory mediators were measured. Results: Intrarectal pretreatment with NPC 15669 results in a significant reduction of all measured indices of inflammation. The median effective dose (ED50) of NPC 15669 for inhibition of MPO accumulation and vascular permeability is 13.2 mg/kg and 31 mg/kg, respectively. The active moiety of sulfasalazine, 5-aminosalicylic acid (5-ASA), the antioxidant/5-lipoxygenase inhibitor, nordihydroguaiaretic acid (NDGA) and the corticosteroids dexamethasone and hydrocortisone, yielded ED50 values (MPO accumulation) of 68 mg/kg, 95 mg/kg, 0.7 mg/kg, and 13 mg/kg, respectively. When formulated suspensions of NPC 15669, 5-ASA, or dexamethasone were used, potency was increased 10-40-fold. Furthermore, NPC 15669 (10 mg/kg) administered 7 hours after acetic acid and evaluated 24 hours after acetic acid administration significantly attenuated neutrophil influx (70% inhibition of MPO accumulation), whereas 5-ASA (100 mg/kg) displayed no therapeutic effects. Conclusions: NPC 15669 may be useful in the treatment of inflammatory disorders.

During trauma and surgery, bleeding is a major concern. One of the crucial strategies for hemostasis is the use of biological hemostatic material. Herein, we reported an amino acid-based hydrogel FmocF-ADP hydrogel, which consisted of N-[(9H-fluoren-9-ylmethoxy) carbonyl]-3-phenyl-L-alanine (FmocF) and adenosine diphosphate (ADP) sodium solution. The hydrogel was created by FmocF self-assembling to nanofiber in ADP sodium solution and then cross-linking to hydrogel. FmocF-ADP hydrogel showed good in vitro coagulation activity as measured by whole blood clotting assays, platelet clotting assays, platelet activation assays, and platelet adhesion assays. Further, it was noted to reveal an exceptional in vivo hemostatic effect in a mouse liver bleeding model. Together with the previous report of the good biocompatibility and antimicrobial activity of FmocF hydrogel, our study would extend the biomedical application of FmocF hydrogel. In conclusion, the present study would provide a constructive strategy for the development of new antimicrobial and hemostatic materials or develop a potential hemostatic material.